spacer
home > pmps > winter 2018 > stamp of approval
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Stamp of Approval

Over the past 10 years, Good Distribution Practice (GDP) has become something of a buzzword when discussing best practice within the pharmaceutical logistics industry. However, a vast amount of confusion remains over its meaning, especially when it comes to which guidelines and licenses apply to each part of the supply chain.

Part of the problem lies in the fact that there is no single global standard. While the WHO provides global guidance, levels of GDP compliance vary significantly across the world. Each country has its own interpretation of exactly what GDP entails, and these are usually influenced by one of three regions: the EU, US, and the rest of the world. Generally speaking, the more advanced the country, the more comprehensive the GDP guidelines will be.

However, it is interesting to note that, within the US Pharmacopeia (USP), which provides guidance to the US pharma industry, there has been a significant focus on supply chain security, with less emphasis on GDP as a whole. This is currently being reviewed, with the revision of Chapter 1079, in line with the introduction of the Drug Quality and Security Act (DQSA), sometimes referred to as ‘track-and-trace’. The DQSA means that supply chain integrity and GDP compliance within the US are now being addressed by the FDA, and it is the USP’s goal to provide supplementary clarification and guidance on the requirements set out in the DQSA (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Amy Shortman has 20 years’ experience within pharma and healthcare logistics. During this time, she has worked in operations, sales, and business development. In 2011, Amy founded ASC Associates to fulfil the increasing demand for expertise in compliant and secure supply chains and has since developed a global team of experts that can advise, support, and connect teams throughout the entire supply chain. She also works with IATA as an External Instructor for CEIV and is a Chartered Fellow of The Institute of Logistics and Transport, UK.  

Henry Moran has over 20 years’ experience within the logistics industry, having worked in numerous roles in hi-tech electronics, global logistics, and freight forwarding. Additionally, he has a master’s in business studies, specialising in manufacturing and logistics and is a practising six sigma black belt. Henry now focuses on supporting clients to assess, secure, and develop compliant supply chains through his work with ASC Associates.

spacer
Amy Shortman
spacer
spacer
spacer
Henry Moran
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Quanticate Partners with CluePoints to Offer Data Quality Oversight capabilities

Quanticate, a data-focused clinical research organisation (CRO), has announced that it has partnered with CluePoints as part of its new Data Quality Oversight service.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

Cell Therapy Manufacturing & Gene Therapy Congress

4-6 December 2018, RAI, Amsterdam

Bringing together 300+ leaders and key influencers from pharma and biotech companies on 4 - 6 December 2018 in Amsterdam, Cell Therapy Manufacturing & Gene Therapy will provide you with the latest advice for transforming innovative research to prosperous cell & gene therapy manufacturing.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement